Biotechnology company United Therapeutics (NASDAQ: UTHR) will be reporting earnings this Wednesday before the bell. Here’s what to expect.

United Therapeutics missed analysts’ revenue expectations last quarter, reporting revenues of $799.5 million, up 6.8% year on year. It was a softer quarter for the company, with a miss of analysts’ revenue estimates and a significant miss of analysts’ EPS estimates.

Is United Therapeutics a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting United Therapeutics’s revenue to grow 10.1% year on year, slowing from the 19.7% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. United Therapeutics has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at United Therapeutics’s peers in the therapeutics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 1.2%, beating analysts’ expectations by 3.6%, and Halozyme Therapeutics reported revenues up 51.6%, topping estimates by 0.6%. Biogen traded up 4.6% following the results while Halozyme Therapeutics was down 9%.

Read our full analysis of Biogen’s results here and Halozyme Therapeutics’s results here.

The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the therapeutics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.5% on average over the last month. United Therapeutics’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $538.58 (compared to the current share price of $476.63).

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.